Reliability and validity of Chinese version of Xerostomia Questionnaire in nasopharyngeal carcinoma patients undergoing radiotherapy
Wang Lin,Zhu Manyi,Huang Yuqing,Huang Jiawen,Chen Boyu,Di Muping,Miao Jingjing,Zhao Chong
Department of Nasopharyngeal Carcinoma,Sun Yat-sen University Cancer Center,State Key Laboratory of Oncology in South China,Collaborative Innovation Center for Cancer Medicine,Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy,Guangzhou 510060,China
Abstract：Objective To evaluate the validity and reliability of the Chinese version of Xerostomia Questionnaire (XQ-C) in nasopharyngeal carcinoma patients treated with radiotherapy. Methods XQ-C was translated according to the International Quality of Life Assessment project approach. Patients with nasopharyngeal carcinoma in different radiotherapy stages were enrolled in this study and assessed by using the XQ-C. The validity and reliability of the questionnaire results were evaluated. The content validity was assessed by experts grading method. The construct validity was assessed by exploratory factor analysis. The discriminant validity was determined by non-parametric method.The reliability was evaluated by Cronbach′s α and split-half reliability to assess the internal consistency.Results A total of 212 questionnaires were completely filled out. Content validity showed that the item content validity index (I-CVI) ≥0.80,Scale-CVI/Ave=0.97,and P value of Kendall′s W test was 0.701. Exploratory factor analysis revealed that XQ-C was a unidimensional scale. The scale scores of patients at different stages of radiotherapy significantly differed, suggesting that the discriminant validity was good. Cronbach′s α of the scale was 0.951 and Guttman′s semi-reliability coefficient was 0.940. Conclusion The XQ-C is valid and reliable, which can be widely applied in the clinical diagnosis, treatment and research of xerostomia in Chinese nasopharyngeal carcinoma patients after radiotherapy.
Wang Lin,Zhu Manyi,Huang Yuqing et al. Reliability and validity of Chinese version of Xerostomia Questionnaire in nasopharyngeal carcinoma patients undergoing radiotherapy[J]. Chinese Journal of Radiation Oncology, 2019, 28(8): 566-570.
[1] Wee JT,Ha TC,Loong SL,et al. Is nasopharyngeal cancer really a “Cantonese cancer”?[J]. Chin J Cancer,2010,29(3):517-526. [2] Fu KK,Pajak TF,Trotti A,et al. A Radiation Therapy Oncology Group (RTOG) phase Ⅲ randomized study to compare hyper-fractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas:first report of RTOG 9003[J]. Int J Radiat Oncol Biol Phys,2000,48(1):7-16. DOI:10.1016/s0360-3016(00)00663-5. [3] Abendstein H,Nordgren M,Boysen M,et al. Quality oflife and head and neck cancer a 5 year prospective study[J]. Laryngoscope,2005,115(12):2183-21892. DOI:10.1097/01. MLG.0000181507.69620.14 [4] Cox JD,Stetz J,Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)[J]. Int J Radiat Oncol Biol Phys,1995,3l (5):1341-1346.DOI:10.1016/0360-3016(95)00060-C. [5] National Cancer Institute. Common Terminology Criteria for Adverse Events v.3.0and v.4.0(CTCAE).[DB][2018-10-07].http://ctep.cancer.gov/protocol Development/electronic_applications/ctc.htm. Accessed June 14,2011. [6] Rubin P,Constine LS 3rd,Fajardo LF,et al. Overview of late effects normal tissues (LENT) scoring system[J]. Radiother Oncol,1995,35(1):9-10. DOI:10.1016/0167-8140(95)97447-l. [7] Eisbruch A,Kim HM,Terrell JE,et al. Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer[J]. Int J Ptadiat Oncol Biol Phys,2001,50(3):695-704. DOI:10.1016/s0360-3016(01)01512-7. [8] Pellegrino F,Groff E,Bastiani L,et al. Assessment of radiation-induced xerostomia:validation of the Italian version of the xerostomia questionnaire in head and neck cancer patients[J]. Support Care Cancer,2015,23(4):925-932. DOI 10.1007/s00520-014-2438-2. [9] Memtsa PT,Tolia M,Tzitzikas I,et al. Validity and reliabilityof theGreek version of the xerostomia questionnaire in head and neck cancer patients[J]. Support Care Cancer,2017,25(3):847-853. DOI:10.1007/s00520-016-3471-0. [10] Lin SC,Jen YM,Chang YC,et al. Assessment of xerostomia and its impact on quality of life in head and neck cancer patients undergoing radiotherapy,and validation of the Taiwanese version of the xerostomia questionnaire[J]. J Pain Symptom Manag,2008,36(2):141–148. DOI:10.1016/j.jpainsymman.2007.09.009. [11] Gandek B,Ware JE. Methods for Validating and Norming Translations of Health Status Questionnaires[J]. J Clin Epidemiol,1998,51(11):953-959. DOI:10.1016/s0895-4356(98)00086-9. [12] Yeh SA,Tang Y,Lui CC,et al. Treatment outcomes and late complications of 849 patients with nasopharyngeal cacinoma treated with radiotherapy alone[J]. Int J Radiat Oncol Biol Phys,2005,62(3):672-679. DOI:10.1016/j.ijrobp.2004.11.002. [13] Lee N,Xia P,Quivey JM,et al. Intensity modulated radiotherapy in the treatment of nasopharyngeal carcinoma:An update of the UCSF experience[J]. Int J Radiat Oncol Biol Phys,2002,53(1):12-22. DOI:10.1016/s0360-3016(02)02724-4. [14] Zheng Y,Han F,Xiao W,et al. Analysis of late toxicity in nasopharyngeal carcinoma patients treated with intensity modulated radiation therapy[J]. Radiat Oncol,2015,10(1):17. DOI:10.1186/s13014-014-0326-z. [15] Tenhunen M,Collan J,Kouri M,et al. Scintigraphyin prediction of the salivary gland function after galand-sparing intensity modulated radiation therapy for head and neck cancer[J]. Radiother Oncol,2008,87(2):260-267. DOI:10.1016/j.radonc.2008.02.017. [16] Astreinidou E,Roesink JM,Raaijmakers CP,et al.3D MR sialography as a tool to investigate radiation-induced xerostomia:feasibility study[J]. Int J Radiat Oncol Biol Phys,2007,68(5):1310-1319. DOI:10.1016/j.ijrobp.2007.01.062. [17] Dirix P,De Keyzer F,Vandecaveye V,et al. Diffusion-weightedmagnetic resonance imaging to evaluate majorsalivary glandfunction before and after radiotherapy[J]. Int J Radiat Oncol Biol Phys,2008,71(5):1365-1371. DOI:10.1016/j.ijrobp.2007.12.011. [18] Meirovitz A,Murdoch-Kinch CA,Schipper M,et al. Grading xerostomia by physicians or by patients after IMRT of head and neck cancer[J]. Int J Radiat Oncol Biol Phys,2006,66(2):445-453. DOI:10.1016/j.ijrobp.2006.05.002. [19] Aaronson NK,Ahmedzai S,Bergman B,et al. The European organization for research and treatment of cancer QLQ-C30:a quality-of-life instrument for use in international clinical trials in oncology[J]. J Natl Cancer Inst,1993,85(5):365-376. DOI:10.1093/jnci/85.5.365. [20] Bjordal K,Hammerlid E,Ahlner-Elmqvist M,et al. Quality of life in head and neck cancer patients:validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire- H&N 35[J]. J Clin Oncol,1999,17(3):1008-1008. DOI:10.1200/jco.1999.17.3.1008. [21] Wan Leung S,Lee TF,Chien CY,et al. Health-related Quality of life in 640 head and neck cancer survivors after radiotherapy using EORTC QLQ-C30 and QLQ- H&N 35 questionnaires[J]. BMC Cancer,2011,11(1):128. DOI:10.1186/1471-2407-11-128. [22] Eisbruch A,Rhodus N,Rosenthal D,et al. How should we measure and report radiotherapy-induced xerostomia?[J]. Semin Radiat Oncol,2003,13(3):226-234. DOI:10.1016/S1053-4296(03)00033-X. [23] Eisbruch A,Marsh LH,Dawson LA,et al. Recurrences near base of skull after IMRT for head-and-neck cancer:implications for target delineation in high neck and for parotid gland sparing[J]. Int J Radiat Oncol Biol Phys,2004,59(1):28-42. DOI:10.1016/j.ijrobp.2003.10.032. [24] Polit DF,Beck CT,Owen SV. Is the CVI an acceptable indicator of content validity? Appraisal and recommendations[J]. Res Nur Heal,2007,30(4):459-467. DOI:10.1002/nur.20199. [25] Kam MK,Teo PM,Chau RM,et al. Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy:the Hong Kong experience[J]. Int J Radiat Oncol Biol Phys,2004,60(5):1440-1450. DOI:10.1016/j.ijrobp.2004.05.022. [26] Xiao WW,Huang SM,Han F,et al. Local control,survival,and late toxicities of locally advanced nasopharyngeal carcinoma treated by simultaneous modulated accelerated radiotherapy combined with cisplatin concurrent chemotherapy[J]. Cancer,2010,117(9):1874-1883. DOI:10.1002/cncr.25754.
2019, Vol. 28 
